| Bioactivity | AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases CDK1, CDK2, and CDK4 with Ki values in the 1-3 nM range[1]. AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis[3]. | ||||||||||||
| Invitro | AG-024322 (0.1-30 μM; 24 hours) is less toxic at concentrations below 3 µM, the viability of human PBMCs as measured by ATP content with a TC50 value of 1.4 µM for human PBMCs[2].AG-024322 (0-120 nM) exhibits growth inhibition effects on HCT-116 cells. It is slightly less potent in the functional cellular assay with an IC50 of 120 nM[2]. | ||||||||||||
| Name | AG-024322 | ||||||||||||
| CAS | 837364-57-5 | ||||||||||||
| Formula | C23H20F2N6 | ||||||||||||
| Molar Mass | 418.44 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
AG-024322
CAS: 837364-57-5 F: C23H20F2N6 W: 418.44
AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases CDK1, CDK2, and CDK4 with Ki values i
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.